Nephrology Drugs Market Updates : Key Developments, Investment Opportunities, and Forecast 2021-2030

According to a new report published by Allied Market Research, titled, "Global Nephrology Drugs Market by drug class, route of administration, distribution channel, and region: Global Opportunity Analysis and Industry Forecast, 2021-2030," the global nephrology drugs market was valued at $14,501.75 million in 2020, and is projected to reach $23,405.42 million by 2030, registering a CAGR of 5.0% from 2021 to 2030.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/A13396

Key drivers propelling the nephrology market forward include heightened research and development activities for both new drug introductions and enhancements to existing medications. Additionally, the uptick in approvals from government regulatory bodies presents lucrative prospects for market expansion. Noteworthy examples include AstraZeneca's Farxiga receiving FDA approval in April 2021, and Bayer's FDA approval for Finerenone in July 2021. Furthermore, escalated investment in R&D activities is amplifying the demand for nephrology drugs, thus stimulating market growth. However, concerns over treatment-related side effects and the high cost of drugs pose challenges to market progression.

Chronic kidney diseases constitute a significant global public health challenge, with a prevalence estimated at 13.4% worldwide, according to the National Library of Medicine. Moreover, the number of patients requiring renal replacement therapy due to end-stage kidney disease ranges between 4.902 and 7.083 million globally. The increasing incidence of chronic kidney diseases, largely attributed to rising prevalence of conditions such as diabetes mellitus, obesity, hypertension, infections, and aging, underscores the imperative for nephrology drugs. This demand surge is expected to propel market growth in the foreseeable future, as chronic kidney disease directly impacts cardiovascular health, thereby influencing global morbidity and mortality rates.

The market is further propelled by the proliferation of approvals and product launches by key players and biopharmaceutical firms, coupled with technological advancements in nephrology drugs. The burgeoning demand and awareness of nephrology drugs, particularly in developing economies, have spurred research efforts worldwide. Baxter's endorsement of the Administration's Advancing American Kidney Health Initiative in July 2019 underscores industry commitment to addressing kidney-related healthcare challenges. Additionally, substantial investments by Medicare, exceeding $114 billion annually on chronic kidney disease patients in fiscal year 2020, including $35 billion on end-stage renal disease (ESRD) patients, augur well for market expansion opportunities.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-for-customization/A13396

Segmentation of the nephrology drugs market based on drug class, route of administration, distribution channel, and region underscores varied market dynamics. ACE inhibitors, calcium channel blockers, beta blockers, diuretics, and others constitute key drug classes. Among these, ACE inhibitors dominated the market in 2020, driven by rising prevalence of cardiovascular and hypertension conditions and shifting lifestyles. Oral administration remains predominant, with retail pharmacies emerging as the primary distribution channel, reflecting advancements in medical infrastructure and increased public healthcare spending.

North America held the lion's share of the global nephrology drugs market in 2020, with anticipated continued dominance owing to heightened awareness of chronic kidney diseases in the region.

𝐅𝐨𝐫 𝐌𝐨𝐫𝐞 𝐃𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐚𝐧𝐝 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 https://www.alliedmarketresearch.com/nephrology-drugs-market-A13396

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Follow Us on Blog: https://www.dailyreportsworld.com/

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view of providing business insights and consulting to assist its clients in making strategic business decisions and achieving sustainable growth in their respective market domain.

We have professional corporate relations with various companies and this helps us dig out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high-quality of data and help clients in every way possible to achieve success. Each and every piece of data presented in the reports published by us is extracted through primary interviews with top officials from leading companies in domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.